Ranbaxy Laboratories (Ranbaxy) and HNG Chembio Pharmacy (HNG) have reported the transfer of Ranbaxy group’s entire shareholding in Ranbaxy Guangzhou China (RGCL) to HNG Chembio Pharmacy. RGCL was
Alnylam Pharmaceuticals (Alnylam) and collaborators from the David Koch Institute for Integrative Research at the Massachusetts Institute of Technology (MIT) have published new data in the journal Proceedings
Biostar Pharmaceuticals (Biostar) has completed preparation to launch Xin Aoxing Oleanolic Acid capsules in Beijing and Shanghai in early January 2010. The capsules are meant for the treatment
Kalgene Pharmaceuticals (Kalgene) has signed a commercial agreement to have Affomix utilise its Y2HExpress technology to select antibodies with potential diagnostic and therapeutic utility in breast cancer. As
The US Patent & Trademark Office (USPTO) has granted reissue patent RE41,065 to OSI Pharmaceuticals (OSI) replacing Tarceva’s (erlotinib) composition of matter patent (formerly No.5,747,498). The company had
AspenBio Pharma has reported its progress and plans for the premarket notification 510(k) submission of its ELISA format ‘AppyScore’ test. AppyScore is the first blood-based test designed to
The Brazil Patent and Trademark Office has issued patent number 9608799-4 to Theratechnologies, entitled ‘Chimeric fatty body-pro-GRF analog with increased biological potency and pharmaceutical formulation’ for its lead-compound,
Emerging Healthcare Solutions has reported the execution of an exclusive option agreement with ThromboVision, which has developed and patented T-Guide, a new diagnostic test to assist medical professionals
The FDA has granted tentative approval to Glenmark Generics US (GGI), a subsidiary of Glenmark Generics, for Pramipexole Dihydrochloride tablets, the generic version of Boehringer Ingelheim’s Mirapex tablets.
Ohm Laboratories (Ohm), a wholly-owed subsidiary of Ranbaxy Laboratories, has received a warning letter from the FDA for its liquid manufacturing facility located in Gloversville, New York. The
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.